Article thumbnail

Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

By Kawin Leelawat, Siriluck Narong, Jerasak Wannaprasert and Surang Leelawat


Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and 50 benign biliary tract disease cases were randomly selected from a cohort of consecutive cases of biliary tract diseases. Their sera were measured for the levels of NGAL and the widely used serum cholangiocarcinoma marker, carbohydrate antigen 19-9 (CA19-9). Results. The serum CA19-9 and NGAL levels were significantly elevated in cholangiocarcinoma patients (CA19-9: P < .001, NGAL: P < .001). The area under the curve (AUC) of a receiver operating characteristic (ROC) curve analysis for the diagnosis of cholangiocarcinoma of CA19-9 and NGAL was 0.81 and 0.79, respectively. Conclusion. The diagnostic accuracy of serum NGAL and CA19-9 makes them good candidates for use as biomarkers to discriminate cholangiocarcinoma patients from benign biliary tract disease patients

Topics: Clinical Study
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A .F r i e d l ,S .P .S t o e s z ,P .B u c k l e y ,a n dM .N .G o u l d ,“ N e u -trophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression,”
  2. (1999). A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis,”
  3. (1983). A method of comparing the areas under receiver operating characteristic curves derived from the same cases,”
  4. (2005). A.O.O.Chan,K.-M.Chu,S.K.Lametal.,“Earlypredictionof tumor recurrence after curative resection of gastric carcinoma by measuring soluble
  5. (2008). Cholangiocarcinoma: lessons from Thailand,” Current Opinion
  6. (1995). Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow andovariancancercells,”FEBSLetters,vol.357,no.3,pp.255– 259,
  7. (2009). Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy,”
  8. (2008). Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia,”
  9. (2006). Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells,”
  10. Figlin et al., “Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble
  11. (1998). Heterogeneous expression of the lipocalin NGAL in primary breast cancers,”
  12. (2010). Hilar inflammatory pseudotumor mimicking hilar cholangiocarcinoma,”
  13. (2010). Neutrophil gelatinase-associated lipocalin in dialyzed patients is related to residual renal function, type of renal replacement therapy and inflammation,”
  14. (2010). NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing
  15. (2008). Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design,”
  16. (1995). R a m a g e ,A .D o n a g h y ,J .M .F a r r a n t ,R .I o r n s ,a n d R. Williams, “Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis,”
  17. (2001). Ringn´ e r ,Y .C h e ne ta l . ,“ E s t r o g e nr e c e p t o r status in breast cancer is associated with remarkably distinct gene expression patterns,”
  18. (2008). Significance of the serum level of soluble E-cadherin in patients with
  19. (1996). The lipocalin protein family: structure and function,”